<DOC>
	<DOCNO>NCT00718510</DOCNO>
	<brief_summary>STUDY OBJECTIVES : To determine whether addition L-arginine treatment usual ( TAU ) schizophrenia improve enhances therapeutic efficacy ( positive , negative depressive symptom ) effectiveness antipsychotic treatment STUDY POPULATION : Patients diagnose ( DSM-IV criterion ) schizophrenia schizoaffective disorder Total expect number patient : 14 INVESTIGATIONAL COMPOUND : L-arginine capsule , 3 gram L-arginine give twice day ( total daily dose 6 grams/day ) DURATION OF ACTIVE TREATMENT : 3 week follow wash-out phase 5 day 3 week second treatment phase ( cross-over design ) EVALUATION CRITERIA : Primary ( efficacy ) outcomes : PANSS score . Secondary outcome : Calgary Depression Scale schizophrenia , CGI ; AIMS , UKU-assessment side-effects ASSESSMENT SCHEDULE : Treatment arm 1 : Baseline , week : 1,2,3 , wash-out phase ; week 4 , cross-over phase : treatment phase-2 ; week 5,6,7 STATISTICAL CONSIDERATIONS : Analysis variance outcome measure treatment between-subject factor pre- post-treatment score within- subject factor . DURATION OF STUDY PERIOD : Patient recruitment complete 12 month , study full completion 18 month .</brief_summary>
	<brief_title>L-arginine Treatment Usual Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Aged 1865 year 2 . Diagnoses schizophrenia schizoaffective disorder use Diagnostic Statistical ManualIV ( DSMIV ) criteria 3 . Competent willing give inform consent 4 . Able take oral medication likely complete require evaluation . 5 . Medication remain stable 4 week prior baseline . 6 . Female participant child bear capability must willing use adequate contraceptive ( 4.6.1a ) duration study , , willing pregnancy test pretreatment study . Adequate contraception define use contraceptive double barrier system ( i.e . condom spermicide ) contraceptive implant , oral contraceptive inject depot contraceptive plus form contraceptive , i.e . condom . Females consider incapable child bear one year postmenopausal irreversibly surgically sterilise . Relevant medical illness [ serious renal , diabetes , hepatic , cardiac , low highbloodpressure illnesses ] opinion investigator . In particular , history past recent cardiac illness , MI abnormal ECG current treatment cardiac illness . The result Laboratory Investigations ( LFT , TFT , RFT , WBC , ECG , platelet , blood chemistry , lipid , weight/BMI ) take account determine exclusion criterion . 1 . Relevant medical illness determine first instance ask patient mental health care team patient medical condition/problems . After consent obtain , research nurse/research doctor access patient 's note necessary communicate his/her GP ass patient eligibility take part clinical trial scrutinise patient 's past medical history , recent blood result , electrocardiogram , well physical test perform patient . If deviation 'norm ' investigator assess eligibility individual patient . 2 . Patients receive active treatment Herpes virus Larginine may counteract benefit lysine treat herpes virus 3 . Patients currently receive NSAIDs drug cause significant stomach gastrointestinal sideeffects 4 . Drugs alter potassium level body , ACE inhibitor potassium spar diuretic 5 . Patients pregnant plan become pregnant use amino acid 6 . Patients breastfeed 7 . Prior history intolerance Larginine 8 . Any significant change psychotropic medication do within previous 4 week 9 . Diagnosis substance abuse ( except nicotine caffeine ) dependence within last three month accord DSMIV criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>